Kairos Pharma’s (KAPA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research report released on Monday,Benzinga reports. The brokerage currently has a $9.00 price target on the stock.

Separately, Maxim Group assumed coverage on Kairos Pharma in a research note on Thursday, March 27th. They set a “buy” rating and a $4.00 price target for the company.

Kairos Pharma Price Performance

NYSEAMERICAN KAPA opened at $0.94 on Monday. Kairos Pharma has a 1-year low of $0.85 and a 1-year high of $4.00. The firm has a 50-day moving average price of $1.29.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.